NASDAQ:EVOK Evoke Pharma Q1 2023 Earnings Report $4.52 +0.13 (+2.96%) Closing price 07/23/2025 04:00 PM EasternExtended Trading$4.46 -0.06 (-1.44%) As of 04:30 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings History Evoke Pharma EPS ResultsActual EPS-$8.04Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AEvoke Pharma Revenue ResultsActual Revenue$0.81 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AEvoke Pharma Announcement DetailsQuarterQ1 2023Date5/15/2023TimeN/AConference Call DateMonday, May 15, 2023Conference Call Time7:00AM ETUpcoming EarningsEvoke Pharma's Q2 2025 earnings is scheduled for Tuesday, August 12, 2025, with a conference call scheduled on Monday, August 11, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Evoke Pharma Earnings HeadlinesEvoke Pharma Receives Notice of Allowance for U.S. Patent ... - NasdaqJuly 11, 2025 | nasdaq.comEvoke Pharma, Inc. Receives Patent Allowance for GIMOTI® in ... - NasdaqJuly 11, 2025 | nasdaq.comI warned you about Nvidia… now look what’s happeningNvidia just got Trump’s greenlight to sell high-powered AI chips to China — and their stock surged 5% before the open. That’s the kind of move Tim Sykes built his XGPT system to trade. It scans AI news in real time, filters the noise, and pinpoints when to strike. He’s now showing exactly how it works — before the next headline hits. | Timothy Sykes (Ad)Evoke Pharma Stock Skyrockets On Patent For Nasal Spray That Eases Stomach Delays; Retail Bulls Pile InJuly 10, 2025 | msn.comEvoke Pharma Receives Notice of Allowance for U.S. Patent Application for GIMOTI Extending Orange Book listings to 2036July 9, 2025 | globenewswire.comBreakeven On The Horizon For Evoke Pharma, Inc. (NASDAQ:EVOK)June 14, 2025 | finance.yahoo.comSee More Evoke Pharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Evoke Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Evoke Pharma and other key companies, straight to your email. Email Address About Evoke PharmaEvoke Pharma (NASDAQ:EVOK), a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.View Evoke Pharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Is Former Dividend Aristocrat AT&T a Buy After Q2 Earnings?Amazon Stock Rally Hits New Highs: Buy Into Earnings?TSLA Earnings Week: Can Tesla Break Through $350?Netflix Q2 2025 Earnings: What Investors Need to KnowHow Goldman Sachs Earnings Help You Strategize Your PortfolioCitigroup Earnings Could Signal What’s Next for Markets3 Analysts Set $600 Target Ahead of Microsoft Earnings Upcoming Earnings Charter Communications (7/25/2025)AON (7/25/2025)ENI (7/25/2025)HCA Healthcare (7/25/2025)ICICI Bank (7/25/2025)NatWest Group (7/25/2025)Phillips 66 (7/25/2025)Southern Copper (7/25/2025)Cadence Design Systems (7/28/2025)Enterprise Products Partners (7/28/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.